Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib and Paclitaxel in Recurrent Ovarian Cancer
NCT01468909Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2011
- Primary completion
- Jan 2018
- Countries
- 1
01
Overview
A Phase 2 trial of pazopanib in ovarian carcinoma, fallopian tube carcinoma (PFTC), primary peritoneal carcinoma (PPC), sponsored by National Cancer Institute. Started Dec 2011; status: completed.
02
Drugs
pazopanib
03
Conditions
ovarian carcinomafallopian tube carcinoma (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT01468909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01468909.